FORM 6 - K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
The Securities Exchange Act of 1934
For the month of June 2000
Commission File Number 0-29350
VASOGEN INC.
(Translation of Registrant's name into English)
2155 Dunwin Drive, Suite 10, Mississauga, Ontario, L5L 4M1
(Address of principal executive offices)
(Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20-F or Form 40-F.)
Form 20-F X Form 40-F
----- -----
(Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.)
Yes No X
----- -----
This Form 6-K consists of:
A press release issued by Vasogen Inc. on June 23, 2000, entitled: "Vasogen
Announces Option Exercised":
SIGNATURE
---------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
VASOGEN INC.
By ___________________________________
(Name: Christopher Waddick)
(Title: Vice-President, Finance & CFO)
Date: June 26, 2000
<PAGE>
Vasogen Inc. INVESTOR CONTACT
2155 Dunwin Drive Trevor Burns
Mississauga, ON, Canada L5L 4M1 Investor Relations
tel: (905) 569-2265 fax: (905) 569-9231 tel: (905) 569-9065
http://www.vasogen.com e-mail: [email protected]
--------------------------------------------------------------------------------
FOR IMMEDIATE RELEASE
VASOGEN ANNOUNCES OPTION EXERCISED
Toronto, Ontario (June 23, 2000) -- Vasogen Inc. (TSE:VAS; AMEX:MEW) today
announced that, pursuant to the underwriting agreement entered into with
Research Capital Corporation for the issuance and sale of 1.4 million common
shares at a price of $10.00 per share, Research Capital Corporation has
exercised its option to purchase 350,000 shares at the same price. As previously
announced, the Company has granted Research Capital Corporation a 15%
over-allotment option, exercisable until closing.
A short form preliminary prospectus will be filed June 26th with respect to the
offering. Closing is scheduled to take place on or about July 13, 2000.
The Company's cash position at closing, taking into account the net proceeds of
the 1.75 million common share issue, is projected to be approximately $41
million.
Vasogen is focused on developing immune modulation therapies to advance the
treatment of cardiovascular, autoimmune and related inflammatory
diseases. These therapies are designed to target fundamental
disease-causing events, providing safe, effective treatment.
Statements contained in this press release, including those pertaining to
scientific and clinical research, commercialization plans, strategic alliances,
and intellectual property protection, other than statements of historical fact,
are forward-looking statements subject to a number of uncertainties that could
cause actual results to differ materially from statements made.
"For information purposes only. The issue is not being offered to
residents of the United States of America."
